JP7649999B2 - タウオパチーの予防又は治療剤 - Google Patents

タウオパチーの予防又は治療剤 Download PDF

Info

Publication number
JP7649999B2
JP7649999B2 JP2021553473A JP2021553473A JP7649999B2 JP 7649999 B2 JP7649999 B2 JP 7649999B2 JP 2021553473 A JP2021553473 A JP 2021553473A JP 2021553473 A JP2021553473 A JP 2021553473A JP 7649999 B2 JP7649999 B2 JP 7649999B2
Authority
JP
Japan
Prior art keywords
substituted
cycloalkyl
cycloheteroalkyl
tauopathy
tau
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021553473A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021079887A1 (https=
JPWO2021079887A5 (https=
Inventor
治久 井上
恵子 今村
真人 樋口
成彦 佐原
麻衣子 小野
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NATIONAL INSTITUTES FOR QUANTUM AND RADIOLOGICALSCIENCE AND TECHNOLOGY
Kyoto University NUC
Original Assignee
NATIONAL INSTITUTES FOR QUANTUM AND RADIOLOGICALSCIENCE AND TECHNOLOGY
Kyoto University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NATIONAL INSTITUTES FOR QUANTUM AND RADIOLOGICALSCIENCE AND TECHNOLOGY, Kyoto University NUC filed Critical NATIONAL INSTITUTES FOR QUANTUM AND RADIOLOGICALSCIENCE AND TECHNOLOGY
Publication of JPWO2021079887A1 publication Critical patent/JPWO2021079887A1/ja
Publication of JPWO2021079887A5 publication Critical patent/JPWO2021079887A5/ja
Application granted granted Critical
Publication of JP7649999B2 publication Critical patent/JP7649999B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021553473A 2019-10-25 2020-10-20 タウオパチーの予防又は治療剤 Active JP7649999B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019194758 2019-10-25
JP2019194758 2019-10-25
PCT/JP2020/039450 WO2021079887A1 (ja) 2019-10-25 2020-10-20 タウオパチーの予防又は治療剤

Publications (3)

Publication Number Publication Date
JPWO2021079887A1 JPWO2021079887A1 (https=) 2021-04-29
JPWO2021079887A5 JPWO2021079887A5 (https=) 2023-11-17
JP7649999B2 true JP7649999B2 (ja) 2025-03-24

Family

ID=75620677

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021553473A Active JP7649999B2 (ja) 2019-10-25 2020-10-20 タウオパチーの予防又は治療剤

Country Status (7)

Country Link
US (1) US20220296548A1 (https=)
EP (1) EP4049679A4 (https=)
JP (1) JP7649999B2 (https=)
CN (1) CN114599397B (https=)
AU (1) AU2020370758B2 (https=)
CA (1) CA3159067A1 (https=)
WO (1) WO2021079887A1 (https=)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000034226A (ja) 1998-05-15 2000-02-02 Warner Lambert Co 安定化された４―アミノ―３―置換―ブタン酸誘導体含有製剤およびその製造法
JP2005529941A (ja) 2002-06-11 2005-10-06 ゼノポート，インコーポレイテッド Ｇａｂａ類似体のアシルオキシアルキル誘導体の合成法
WO2009041453A1 (ja) 2007-09-28 2009-04-02 Daiichi Sankyo Company, Limited 二環性γ－アミノ酸誘導体

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5084479A (en) * 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
US20020103360A1 (en) 1998-09-01 2002-08-01 Yang Pan Novel protein related to melanoma-inhibiting protein and uses thereof
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
AR061728A1 (es) * 2006-06-30 2008-09-17 Pfizer Prod Inc Composicion para tratamiento usando compuestos selectivos alfa-2-delta-1
EP2018854A1 (en) * 2007-07-27 2009-01-28 Merz Pharma GmbH & Co. KGaA Novel combinations of neramexane for the treatment of neurodegenerative disorders
WO2009029173A1 (en) * 2007-08-23 2009-03-05 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptogenesis
US20110287014A1 (en) * 2008-11-24 2011-11-24 Arnon Rosenthal Antibodies directed against calcium channel subunit alpha2/delta and methods using same
AU2010286501B2 (en) 2009-08-28 2015-06-11 The Board Of Regents Of The University Of Texas System Antibodies that bind Tau oligomers
KR20170085792A (ko) * 2016-01-15 2017-07-25 서울대학교산학협력단 Tsp-1을 포함하는 알츠하이머병 예방 또는 치료용 조성물
JP7162302B2 (ja) * 2016-10-07 2022-10-28 国立大学法人京都大学 Ｆｔｌｄの予防又は治療剤及びそのスクリーニング方法
JP2019194758A (ja) 2018-05-01 2019-11-07 キヤノン株式会社 情報処理装置、情報処理方法、およびプログラム

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000034226A (ja) 1998-05-15 2000-02-02 Warner Lambert Co 安定化された４―アミノ―３―置換―ブタン酸誘導体含有製剤およびその製造法
JP2005529941A (ja) 2002-06-11 2005-10-06 ゼノポート，インコーポレイテッド Ｇａｂａ類似体のアシルオキシアルキル誘導体の合成法
WO2009041453A1 (ja) 2007-09-28 2009-04-02 Daiichi Sankyo Company, Limited 二環性γ－アミノ酸誘導体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SUPASITTHUMRONG T. et al.，Gabapentin and pregabalin to treat aggressivity in dementia: a systematic review and illustrative ca，British Journal of Clinical Pharmacology，2018年，Vol. 85, No. 4，pp. 690-703

Also Published As

Publication number Publication date
WO2021079887A9 (ja) 2022-04-14
EP4049679A1 (en) 2022-08-31
AU2020370758B2 (en) 2025-08-14
CN114599397B (zh) 2024-05-28
JPWO2021079887A1 (https=) 2021-04-29
EP4049679A4 (en) 2023-11-01
US20220296548A1 (en) 2022-09-22
WO2021079887A1 (ja) 2021-04-29
CA3159067A1 (en) 2021-04-29
AU2020370758A1 (en) 2022-06-02
CN114599397A (zh) 2022-06-07

Similar Documents

Publication Publication Date Title
Bassil et al. Improved modeling of human AD with an automated culturing platform for iPSC neurons, astrocytes and microglia
Imbimbo et al. A critical appraisal of tau‐targeting therapies for primary and secondary tauopathies
Price et al. Therapeutic Trem2 activation ameliorates amyloid-beta deposition and improves cognition in the 5XFAD model of amyloid deposition
Jan et al. Activity of translation regulator eukaryotic elongation factor-2 kinase is increased in Parkinson disease brain and its inhibition reduces alpha synuclein toxicity
Johnson et al. CSF1R inhibitors induce a sex-specific resilient microglial phenotype and functional rescue in a tauopathy mouse model
Dunning et al. Direct high affinity interaction between Aβ42 and GSK3α stimulates hyperphosphorylation of tau. A new molecular link in Alzheimer’s disease?
Prati et al. 3, 4-Dihydro-1, 3, 5-triazin-2 (1 H)-ones as the first dual BACE-1/GSK-3β fragment hits against Alzheimer’s disease
US20200338045A1 (en) Isoindoline compositions and methods for treating neurodegenerative disease
Akasaka et al. In vivo near-infrared fluorescence imaging selective for soluble amyloid β aggregates using y-shaped BODIPY derivative
JP6868568B2 (ja) ホスファターゼ選択的および非選択的なホスファターゼ阻害剤を選択するための方法
US20190358238A1 (en) ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES
JP2014524482A (ja) 神経変性疾患を処置する組成物及び方法
US20210079075A1 (en) Novel means and methods for treating neurodegenerative diseases
Dumbacher et al. Modifying Rap1-signalling by targeting Pde6δ is neuroprotective in models of Alzheimer’s disease
McKenzie-Nickson et al. Modulating protein phosphatase 2A rescues disease phenotype in neurodegenerative tauopathies
JP2026053635A (ja) アルツハイマー病を治療するためのｒｈｏキナーゼ阻害剤の使用方法
Hering et al. A manifesto for Alzheimer’s disease drug discovery in the era of disease-modifying therapies
US20230407298A1 (en) Methods for inhibiting chmp7 expression in neuronal cells for the treatment of neurodegenerative disorders
CN112313230B (zh) 用于治疗、缓解或预防与Tau聚集体相关的病症的新型化合物
JP6008305B2 (ja) Ｔａｃｃ３を標的とする小化合物
JP7649999B2 (ja) タウオパチーの予防又は治療剤
AU2020257262A1 (en) Neurogenesis
Lee et al. 4-Acyl-3, 4-dihydropyrrolo [1, 2-a] pyrazine derivative rescued the hippocampal-dependent cognitive decline of 5XFAD transgenic mice by dissociating soluble and insoluble Aβ aggregates
US20240390333A1 (en) Neuroprotective compositions and methods of using the same
HK40075042A (en) Preventative or therapeutic agent for tauopathy

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20220516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231019

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231019

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20231019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231019

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231020

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241119

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20241216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241216

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250228

R150 Certificate of patent or registration of utility model

Ref document number: 7649999

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150